Διαφάνεια: Δημοσιοποίηση παροχών

PUBLICATION OF TRANSFERS OF VALUE

According to article 66 par. 7a of Law 4316/2014, the pharmaceutical companies in Greece are obliged to disclose, either on an aggregate or on an individual basis, on a case-by-case basis, in accordance with the current regulatory framework, any transfers of value granted to Healthcare Professionals (HCPs), Healthcare Organizations (HCOs) and Patient Organizations (POs). In addition, the Disclosure Code of the European Federation of Pharmaceutical Industries and Associations (EFPIA) and the Disclosure Code of the Hellenic Association of Pharmaceutical Companies (SFEE) require their members to publish payments and transfers of value to HCPs, HCOs and POs, in accordance with the applicable regulatory framework.

The transfers of value of TAKEDA HELLAS SA are published by name on this website for the period from 01/01/2023 - 31/12/2023 to Patient Organizations (POs), Healthcare Organizations (HCO), as well as to Healthcare Professionals (HCPs), who have given (regardless of any restrictions and exceptions provided in No. 5 / 2016 opinion of the Personal Data Protection Authority), and have not revoked their relevant consent, or for whom the relevant consent is not required. In any other case, the disclosure of the transfers of value to the HCPs for the respective period of time is done in an aggregate way, in compliance also with Article 3.02 of the Disclosure Code of EFPIA.

It is explicitly pointed out that this publication was formed after the issuance of no. 5/2016 and 2/2017 Opinions of the Personal Data Protection Authority, as well as the relevant Announcements of the National Organization for Medicines in the context of the application of article 66 par. 7 Law 4316/2014 (Government Gazette A’ 270).

We reserve the right to update the above transfers of value in case of issuance of subsequent legislative or regulatory provisions or instructions of the involved administrative bodies. In any case, this disclosure is intended to enhance the transparency of the pharmaceutical companies' relationship with HCPs, HCOs and POs, as well as to defend patients' right to know about the pharmaceutical company's relationship with the scientific community.

It is pointed out that the National Organization for Medicines (N.O.M.) publishes at its own responsibility the data of HCPs based on the reports submitted by the pharmaceutical companies, while the pharmaceutical companies publish on their websites the data of HCPs based on their respective methodological note. Therefore, Takeda does not bear and in any case disclaims any responsibility for the disclosure of HCP data on the relevant publication platform of the N.O.M. website, for which the N.O.M.is solely responsible.

The published data cannot be used for purposes other than the purpose of transparency, which is sought by Law 4316/2014 (article 66) and the Codes of Conduct and Disclosure of SFEE and EFPIA for the Disclosure of Transfers of Value from Pharmaceutical Companies to HCPs, HCOs and POs. The disclosure does not provide a general license, nor does it give a relevant right, to those who visit our website and / or the relevant publication platform of N.O.M.. to undertake additional processing of data of healthcare professionals, such as e.g. cross-referencing of data with information published on the websites of other members of SFEE or EFPIA.

For further explanations regarding the transfers of value that are disclosed, please refer to the relevant Methodological Note 2023.

Disclosure Reports - Εκθέσεις δημοσιοποίησης 2023

• Report (English)
• Report (Greek)
• Methodology (English)
• Methodology (Greek)